All In Biotech

Free tool

FAERS Monitor: Norpramin

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 014399 or its brand name (Norpramin, Desipramine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

279

Serious

185

66% of reports

Hospitalization

88

Death reported

27

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective29
  • fatigue22
  • drug hypersensitivity17
  • nausea17
  • headache16
  • dyspnoea15
  • toxicity to various agents15
  • off label use14
  • confusional state13
  • dizziness12
  • vomiting12
  • depression11
  • gastrooesophageal reflux disease11
  • anxiety10
  • fall10

Reports by year received

View as table
YearReports
200410
200511
20069
20072
20085
20098
201012
201118
201216
20136
201411
201515
201617
201722
201816
201915
202012
20216
20228
202310
202415
202520
202615

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,880 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
gastrooesophageal reflux diseaseSignal1110.35.884
toxicity to various agentsSignal156.74.168
drug hypersensitivitySignal176.64.276
confusional stateSignal136.13.650
depressionSignal113.62.019
anxietySignal102.61.49
fallSignal102.31.26
fatigueSignal222.11.413
dyspnoea152.01.27
vomiting121.91.15
headache161.91.26
dizziness121.81.04
drug ineffective291.71.27
nausea171.61.04
off label use141.20.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.